Rapid growth of Polish biotechnology sector leads to demand for foreign expertise, as Polpharma Biologics announces 70 new vacancies
The new roles come on top of significant growth at the company in the last two years, with an additional 300 employee…
Polpharma Biologics Group announces that its joint venture Bioeq has submitted a biologics license application (BLA) for biosimilar Ranibizumab to the U.S. Food and Drug Administration (FDA)
Polpharma Biologics Group announces that its joint venture company with Santo Holding (Strüngmann Group), Bioeq, has…
Warning against fraudulent internet recruitment activities
Our attention has been drawn to the fraudulent activities of persons posing as recruitment agencies or Polpharma Biol…
European biotechnology company Polpharma Biologics has unveiled a new logo and corporate message as part of an extensive rebranding initiative.
Our new brand represents our passion and dedication to innovation, we utilize the latest technology and cutting-edge…
Cooperation agreement between Polpharma Biologics and the University of Warsaw
Polpharma Biologics and the University of Warsaw have signed a cooperation agreement in an important step toward buil…
Polpharma Biologics announces global commercialization deal for biosimilar natalizumab, a key multiple sclerosis medicine
Polpharma Biologics today announces that it has entered a global commercialization agreement with Sandoz AG for a nat…